Please use this identifier to cite or link to this item: http://dspace.utpl.edu.ec/handle/123456789/19238
Title: Pharmacological effects of PARP inhibitors on cancer and other diseases
Authors: Guaman Ortiz, L.
Keywords: Cancer
Cell death
DNA repair
Inflammation
Neurodegenerative diseases
PARG inhibitors
PARP inhibitors
Poly(ADP-ribosylation)
Tankyrases
Issue Date: 1-Dec-2011
Publisher: Current Enzyme Inhibition
Abstract: Poly(ADP-ribosylation), a post-translational modification of proteins involved in DNA repair, replication, transcription and cell death, consists in the conversion of �-NAD + into ADP-ribose, and the further formation of polymers of variable length and structure bound to nuclear protein acceptors. Polymer synthesis and degradation are performed respectively by poly(ADP-ribose) polymerase (PARP) and poly(ADP-ribose) glycohydrolase (PARG) enzymes. Poly(ADP-ribosylation) represents an emergency reaction to DNA damage; however, PARP overactivation promotes NAD depletion and consequent necrosis, thus exerting a noxious function in many circumstances. The search for chemical compounds able to inhibit poly(ADP-ribosylation) allowed the discovery of new molecules and potent derivatives. Pharmacological inhibition of PARP enzymes is able to reverse the deleterious NAD consumption, thus having a protective role towards many pathological conditions. Of note, the combined treatment of tumors with PARP inhibitors and anticancer drugs has been shown to have a beneficial effect in anticancer therapy. On the whole, pharmacological inactivation of poly(ADP-ribosylation) represents a novel therapeutic strategy to limit cellular injury and to improve the prognosis of a variety of diseases. © 2011 Bentham Science Publishers.
URI: http://dspace.utpl.edu.ec/handle/123456789/19238
ISBN: 15734080
Other Identifiers: 10.2174/157340811799860524
Appears in Collections:Artículos de revistas Científicas

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.